Get the Stockscreener App
0.7107
12.37%
-0.1003
X T L Biopharmaceuticals Ltd Adr stock is traded at $0.7107, with a volume of 42,589.
It is down -12.37% in the last 24 hours and down -32.95% over the past month.
XTL Biopharmaceuticals Ltd is engaged in the development of therapeutics for the treatment of unmet medical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE) and Sjogren's syndrome. hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with multiple myeloma (MM). rHuEPO is used in clinical practice for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia.
See More
Previous Close:
$0.811
Open:
$0.7774
24h Volume:
42,589
Relative Volume:
0.07
Market Cap:
$6.72M
Revenue:
$453.30K
Net Income/Loss:
$-1.03M
P/E Ratio:
-6.2783
EPS:
-0.1132
Net Cash Flow:
-
1W Performance:
-6.66%
1M Performance:
-32.95%
6M Performance:
-85.74%
1Y Performance:
-86.79%
1-Day Range:
$0.7107
$0.78
1-Week Range:
$0.655
$0.811
52-Week Range:
$0.5301
$10.28
X T L Biopharmaceuticals Ltd Adr Stock (XTLB) Company Profile
Name
X T L Biopharmaceuticals Ltd Adr
Sector
Industry
Phone
-
Address
-
Compare XTLB vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XTLB
X T L Biopharmaceuticals Ltd Adr
|
0.7107 | 7.67M | 453.30K | -1.03M | 0 | -0.1132 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.70 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
762.45 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
721.77 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.03 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
291.37 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
X T L Biopharmaceuticals Ltd Adr Stock (XTLB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-08-15 | Initiated | H.C. Wainwright | Buy |
X T L Biopharmaceuticals Ltd Adr Stock (XTLB) Latest News
XTL Biopharmaceuticals Faces Nasdaq Delisting After “Public Shell” Determination - The Globe and Mail
XTL Biopharmaceuticals stock falls on Nasdaq delisting notice - Investing.com
XTL Biopharmaceuticals Shareholders Approve Capital Increase and NeuroNOS-Linked Private Placement - TipRanks
XTL Biopharmaceuticals Faces Liquidation of Web Data Subsidiary After Insolvency Ruling - TipRanks
XTL Biopharmaceuticals Adjourns Extraordinary Shareholders Meeting for Lack of Quorum - The Globe and Mail
XTLB Stock Price, Forecast & Analysis | XTL BIOPHARMACEUTICALS-ADR (NASDAQ:XTLB) - ChartMill
XTL Biopharmaceuticals announces CFO transition amid strategic appointments - MSN
XTL Biopharmaceuticals Advances NeuroNOS Acquisition and Plans $2 Million Private Placement to Address Nasdaq Equity Deficiency - TipRanks
XTL Biopharmaceuticals Faces Subsidiary Insolvency Filing, Reviews $1.5 Million Loan Exposure - TipRanks
XTL Biopharmaceuticals Flags Nasdaq Equity Deficiency, Given Deadline to Regain Compliance - TipRanks
XTL Biopharmaceuticals Calls February 17 Extraordinary Meeting to Expand Share Capital and Approve NeuroNOS-Linked Financing - The Globe and Mail
Beyond Air Deals Autism-Focused NeuroNOS To XTL For Equity, Future Payments - Benzinga
XTL Biopharmaceuticals Moves to Acquire NeuroNOS Stake from Beyond Air and Plans $2 Million Private Placement - TipRanks
XTL Biopharmaceuticals Takes Major Impairment on The Social Proxy in First-Half 2025 Results - The Globe and Mail
XTL Biopharmaceuticals Faces Nasdaq Bid-Price Deficiency, Given Until June 2026 to Regain Compliance - TipRanks
12 Health Care Stocks Moving In Tuesday's After-Market Session - Sahm
XTL Biopharmaceuticals Faces Leadership Changes at Social Proxy Subsidiary - The Globe and Mail
XTL Biopharmaceuticals Announces CFO Transition Amid Strategic Appointments - The Globe and Mail
Total debt per share of XTL Biopharmaceuticals Ltd. Sponsored ADR – LS:A2DK34 - TradingView
These stocks that are showing activity before the opening bell on Friday. - Chartmill
Changes in working capital of XTL Biopharmaceuticals Ltd. Sponsored ADR – FWB:H2K2 - TradingView
XTL Biopharmaceuticals Announces Board Changes Following Resignation - MSN
XTL Biopharmaceuticals: Shifting Gears or Grounded Reality? - StocksToTrade
XTL Biopharmaceuticals Enters Sublicense Agreement with Biossil - TipRanks
XTL Biopharmaceuticals Acquires SOCIAL PROXY LTD. - Nasdaq
symbol__ Stock Quote Price and Forecast - CNN
U.S. shares higher at close of trade; Dow Jones Industrial Average up 1.03% - Investing.com India
Unusual VolumeStock ScreenerNews - Finviz
XTLB Stock Price and Chart — NASDAQ:XTLB - TradingView
XTL Biopharmaceuticals Ltd Share Price ADR Each Repr 100 Shs Spon - Hargreaves Lansdown
XTLB Financial Statements & ChartsX.t.l. Biopharmaceuticals Ltd.Adr MacroTrends - CMLviz
XTLB Pivot Points, Technical Analysis and Moving AveragesX.t.l. Biopharmaceuticals Ltd.Adr Technicals - CMLviz
The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates - Yahoo Finance
List of US Companies Releasing Earnings (EPS) Today - FXLeaders
The Daily Biotech Pulse: Merck Goes Shopping, Nuvectra Files For Bankruptcy Protection, Opiant Rips Higher - Benzinga
XTLB Stock Price and Chart — TASE:XTLB - TradingView
XTLB Stock Price | XTL Biopharmaceuticals Ltd. ADR Stock Quote (U.S.: Nasdaq) - MarketWatch
Check out X T L Biopharmaceuticals Ltd's stock price (XTLB) in real time - CNBC
XTLBX.T.L. Biopharmaceuticals Ltd. ADR Stock Price and Quote - Finviz
INGN Stock Price | Inogen Inc. Stock Quote (U.S.: Nasdaq) - MarketWatch
X T L Biopharmaceuticals Ltd Adr Stock (XTLB) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.07%
0.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):